Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-28P stands for RNA, U4 small nuclear 28, pseudogene. It is classified as a pseudogene and does not code for a functional protein or RNA involved in cellular processes. Pseudogenes are typically non-functional remnants of genes that have lost their ability to encode functional products due to mutations or genomic rearrangements. There is currently no evidence that RNU4-28P serves as a receptor, enzyme, transporter, or any established drug target. It is not reported in the literature as being involved in disease, as a biomarker, or as pharmacologically actionable. The “U4” small nuclear RNAs (snRNAs) themselves are known to be involved with the spliceosome and pre-mRNA splicing, but the "-28, pseudogene" form (RNU4-28P) does not have a described biological function and is not discussed in therapeutic contexts[1]. Note: There is an unrelated, functionally significant gene termed RNU4-2 (RNA, U4 small nuclear 2), which is an active non-coding RNA and a component of the spliceosome implicated in neurodevelopmental disorders[3][5][6][7]. The "-28, pseudogene" variant specified in this query, however, has no such evidence for function or clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 28, pseudogene (RNU4-28P).